Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Health Canada, European Commission Approve Subcutaneous Nivolumab in the Same Solid Tumor Indications as IV Formulation

May 28th 2025

Nivolumab has been approved for subcutaneous use across several adult solid tumor indications that have an existing indication for intravenous use.

Liso-Cel and Pirtobrutinib Add Options in R/R CLL, Underscoring the Importance of Proper Treatment Selection

May 23rd 2025

Seema A. Bhat, MD, discusses the current treatment landscape of chronic lymphocytic leukemia in light of the FDA approvals of liso-cel and pirtobrutinib.

Inavolisib Plus Palbociclib and Fulvestrant Improves OS in PIK3CA-Mutant, HR+/HER2– Breast Cancer

May 22nd 2025

Inavolisib plus palbociclib and fulvestrant improved OS in PIK3CA-mutant, HR-positive, HER2-negative, endocrine-resistant advanced breast cancer.

First-Line Maintenance Lurbinectedin Plus Atezolizumab Boosts Survival in ES-SCLC

May 22nd 2025

IMforte data highlight potential for lurbinectedin plus atezolizumab to become a new SOC for first-line maintenance treatment in ES-SCLC.

Artificial Intelligence Proves Its Worth in Cancer Treatment, Drug Development, and Other Real-World Applications

May 22nd 2025

Multiple experts on artificial intelligence in cancer care discuss its ever-expanding role in several areas of oncology.

China’s NMPA Approves Tafasitamab Plus Lenalidomide in Transplant-Ineligible R/R DLBCL

May 21st 2025

Tafasitamab plus lenalidomide has received NMPA approval for patients with relapsed/refractory DLBCL who are ineligible for ASCT.

Cortice Biosciences Transfers Orphan Drug Designations for TPI 287 in Brain Cancer and CNS Diseases

May 21st 2025

CNS Pharmaceuticals has acquired the orphan drug designations for TPI 287 in gliomas, pediatric neuroblastoma, and progressive supranuclear palsy.

Gastrointestinal Cancer Experts Spotlight the Most Exciting Abstracts Ahead of the 2025 ASCO Annual Meeting

May 21st 2025

Ahead of the 2025 ASCO Annual Meeting, experts in gastrointestinal cancers provide their top anticipated studies they will be watching for at the meeting.

Cemiplimab Displays Survival Benefits Over Chemotherapy in First-Line Advanced PD-L1–High NSCLC With Brain Metastases

May 17th 2025

First-line cemiplimab extended median PFS and OS vs chemotherapy in patients with untreated advanced NSCLC with brain metastases.

T-DM1 Plus Palbociclib Displays Activity in HER2+ Metastatic Breast Cancer

May 16th 2025

T-DM1 plus palbociclib showed significant PFS in patients with HER2-positive metastatic breast cancer.

Pretreatment ctDNA Status Is Associated With Distant Recurrent-Free Survival in Early Breast Cancer

May 16th 2025

Baseline ctDNA concentration was shown to be the most significant predictor of distant recurrence-free survival in patients with early breast cancer.

European Commission Approves Perioperative Nivolumab and Chemotherapy for Resectable PD-L1+ NSCLC

May 16th 2025

Perioperative nivolumab plus chemotherapy was approved by the European Commission for use in resectable PD-L1–positive non–small cell lung cancer.

Adjuvant Pertuzumab Plus Trastuzumab and Chemotherapy Leads to OS Benefit in Early-Stage HER2+ Breast Cancer

May 15th 2025

Adjuvant pertuzumab with trastuzumab and chemotherapy extended OS vs placebo with trastuzumab and chemotherapy in HER2-positive early breast cancer.

T-DXd Improves All Outcomes in Post-Hoc Look of DESTINY-Breast06 in HR+, HER2-Low/-Ultralow Metastatic Breast Cancer

May 15th 2025

Treatment with T-DXd improved outcomes vs chemotherapy in pretreated patients with HR-positive, HER2-low/-ultralow metastatic breast cancer.

Lung Cancer Experts Highlight the Most Anticipated Abstracts at the 2025 ASCO Annual Meeting

May 15th 2025

Ahead of the 2025 ASCO Annual Meeting, lung cancer experts highlight the abstracts and related trials they’re looking forward to seeing at the meeting.

Generic Eltrombopag Is Now Available for Severe Aplastic Anemia and Immune Thrombocytopenia

May 14th 2025

Generic formulations of eltrombopag are now available for severe aplastic anemia and immune thrombocytopenia.

Genetic Insights and Novel Trial Designs Contribute to an Era of Individualized MDS Management

May 13th 2025

Rami Komrokji, MD, discusses the evolution of lower-risk MDS treatments that reflect novel classification systems and trials exploring novel therapies.

Targeted CAR T-Cell Therapies Show Early Efficacy in Solid Tumors With Focus on Mitigating Toxicity

May 12th 2025

Renier Brentjens, MD, PhD, discusses the current landscape of CAR T-cell agents in patients with solid tumors.

Dr Graham on the Significance of the FDA Approval of Mirvetuximab Soravtansine in Ovarian Cancer

May 12th 2025

Deena M. Atieh Graham, MD, discusses the FDA approval of mirvetuximab soravtansine.

Patients With Progressive CLL After Zanubrutinib or Ibrutinib Therapy Often Do Not Have BTK-Mutated Disease

May 11th 2025

BTK mutations occurred at low rates in patients with CLL who had disease progression after receiving zanubrutinib or ibrutinib in the phase 3 ALPINE study.